Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefmenoxime therapy in bacterial osteomyelitis.

T G Sheftel, G Cierny, J L Lefrock

    The American Journal of Medicine
    |December 21, 1984
    PubMed
    Summary

    Cefmenoxime effectively treated osteomyelitis in 15 patients, with 67% achieving arrest. This new cephalosporin showed good safety, with only minor transaminase elevations in two patients during this antibiotic study.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Treatment of osseous cryptococcosis report of a case and review of the literature.

    Orthopedics·2014
    Same author

    Adult chronic osteomyelitis.

    Orthopedics·2014
    Same author

    Bone penetration of antibiotics.

    Orthopedics·2014
    Same author

    The future of spinal cord stereotaxy.

    Bratislavske lekarske listy·2013
    Same author

    Considerations on physiological mechanisms of spinal cord movement performance according to cerebral stimuli.

    Bratislavske lekarske listy·2008
    Same author

    [Reflection on the physiological mechanisms of movements controlled by the spinal cord-brain interaction].

    Casopis lekaru ceskych·2007

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Orthopedic Surgery

    Background:

    • Osteomyelitis is a serious bone infection often requiring prolonged treatment.
    • Beta-lactamase-resistant cephalosporins are crucial for combating bacterial infections.
    • Cefmenoxime is a novel parenteral antibiotic for potential use in challenging infections.

    Purpose of the Study:

    • To evaluate the safety and efficacy of cefmenoxime in patients with osteomyelitis.
    • To determine the antimicrobial spectrum and minimum inhibitory concentrations (MICs) of cefmenoxime against osteomyelitis pathogens.
    • To assess treatment outcomes and toxicity associated with cefmenoxime therapy.

    Main Methods:

    • A cohort of 15 patients with acute or chronic osteomyelitis received cefmenoxime (mean 9.1 g/day) for a mean of 47.3 days.
    • Diagnosis was confirmed by surgical biopsy culture.
    • MICs of cefmenoxime were determined for isolated pathogens.
    • Patients underwent surgical debridement, and outcomes were monitored post-treatment.

    Main Results:

    • Staphylococcus aureus was the most common pathogen identified.
    • Cefmenoxime demonstrated potent activity, with MICs ≤12.5 µg/ml for most pathogens.
    • Ten out of 15 patients (67%) achieved arrest of their osteomyelitis.
    • Two patients experienced mild elevations in transaminases, indicating good overall safety.

    Conclusions:

    • Cefmenoxime is a safe and effective antibiotic for treating osteomyelitis.
    • The drug's efficacy is supported by clinical outcomes and in vitro susceptibility data.
    • Further research may explore cefmenoxime's role in managing bone infections.

    Related Experiment Videos